Biognosys, a Swiss next-generation proteomics company, has secured significant funding from a corporate investment fund. The company is using the Series-C financing round to establish business development and service operations in the US and to develop new workflows and products for high-content protein analysis. Biognosys’ new operations will be established in Boston, which is home to one of the largest biopharma clusters in the US.
Biognosys has a strong, reputable international investor base and an excellent scientific and management team led by CEO and co-founder of Biognosys Dr. Oliver Rinner who says: ‘We believe that the ability to decode the proteome is key for a better understanding of life and will help to develop better drugs, crops, diagnostics and biomaterials in the future. Our mission is to enable researchers to effortlessly analyze whole proteomes by providing superior and easy to use analytical technology’.